ASSOCIATION OF INTRAVESICAL PROSTATIC PROTRUSION GRADE AND THE OUTCOME OF ALPHA BLOCKER TREATMENT FOR BLADDER OUTFLOW OBSTRUCTION

HA BUMBIA; NH SOOMRO; A JAVED; MM ASLAM; GM HIRAJ; SU REHMAN

doi:10.54112/bcsrj.v2023i1.349

Authors

HA BUMBIA Department of Urology, Dr Ziauddin Hospital, Karachi, Pakistan
NH SOOMRO Department of Urology, Hospital, Jacobabad Institute of Medical Science (JIMS), Pakistan
A JAVED Department of Urology, Dr Ziauddin Hospital, Karachi, Pakistan
MM ASLAM Department of Urology, Shahida Islam Teaching Hospital, Lodhran, Pakistan
GM HIRAJ Department of Urology, Amina Inayat Medical College Sheikhupura, Pakistan
SU REHMAN Department of Urology, Kidney Centre, Bahawal Victoria Hospital, Bahawalpur, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2023i1.349

Keywords:

Alpha Blocker Treatment, Bladder Outflow Obstruction, Intravesical Prostratic Protrusion, International Prostate Symptoms Score (IPSS) & Benign Prostatic Hyperplasia (BPH).

Abstract

Benign Prostatic Hyperplasia (B.P.H) affects up to 80% of men older than 45 years of age worldwide, half of whom will eventually require treatment for its clinical manifestations such as bladder outflow obstruction (BOO) and its associated symptoms. There are various treatment strategies for B.P.H; alpha blockers being the most commonly employed. However, the outcome of said pharmacologic agent in treatment of BOO, in the presence of intra-vesical prostatic protrusion (IPP) of varying grades is less researched. The aim of the current study was to study the association IPP grade and the outcome of BOO treatment among patients with BPH. This prospective cohort comprised of a sample of 100 B.P.H patients, aged ≥ 45 years (chosen via non-probability – consecutive sampling), presenting to Ziauddin University Hospital, Karachi from June 2019 to December 2019. After taking written informed consent, data was recorded onto a pre-structured questionnaire containing inquiries pertaining to basic biodata, sociodemographic details, disease particulars, treatment outcome (gauged using IPSS, UFM and PVR) assessed at first contact and again after 1 and 3 months. The data obtained was analyzed using SPSS v. 21.0. The mean age of the sample stood at 68 years (SD ± 10.3).The mean prostate size was recorded to be 58 cm3 (SD ± 32) . The commonest grade of IPP was II (45%), followed by grade I (29%) and grade III (24%). The cumulative treatment outcome was poor, with only a meagre improvement (9.1% in IPSS score, 4% in UFM value and 13% in PVR) was recorded. Stratification revealed that the treatment outcome became progressively worse with increasing grade of IPP. After careful consideration, it can be concluded that the outcome of alpha blocker treatment for BOO among patients with IPP is poor. IPP serves to seemingly dampen the effect of alpha blockers with increasing grades corresponding to progressively worse outcome. Thus, additional modalities may be employed to supplement alphab blocker treatment for better patient outcome among patients with IPP.

Downloads

Download data is not yet available.

References

Awan, K. H., Awan, R. H., Nayab, S., and Awan, F. M. (2019). PROSTATIC HYPERPLASIA (BPH);: TAMSULOSIN WITH AND WITHOUT TOLTERODINE IN PATIENTS HAVING BENIGN PROSTATIC HYPERPLASIA (BPH) WITH IRRITATIVE (OVERACTIVE BLADDER) SYMPTOMS. The Professional Medical Journal 26, 260-263.

Chia, S., Heng, C., Chan, S., and Foo, K. (2003). Correlation of intravesical prostatic protrusion with bladder outlet obstruction. BJU international 91, 371-374.

D’Agate, S., Wilson, T., Adalig, B., Manyak, M., Palacios-Moreno, J. M., Chavan, C., Oelke, M., Roehrborn, C., and Della Pasqua, O. (2020). Impact of disease progression on individual IPSS trajectories and consequences of immediate versus delayed start of treatment in patients with moderate or severe LUTS associated with BPH. World journal of urology 38, 463-472.

de la Rosette, J. J., Alivizatos, G., Madersbacher, S., Perachino, M., Thomas, D., Desgrandchamps, F., and de Wildt, M. (2001). EAU Guidelines on benign prostatic hyperplasia (BPH). European urology 40, 256-263.

Dias, J. S. (2012). Benign prostatic hyperplasia: clinical manifestations and evaluation. Techniques in vascular and interventional radiology 15, 265-269.

Fox, S. H., and Brotchie, J. M. (2010). The MPTP-lesioned non-human primate models of Parkinson’s disease. Past, present, and future. Progress in brain research 184, 133-157.

Lee, L. S., Sim, H. G., Lim, K. B., Wang, D., and Foo, K. T. (2010). Intravesical prostatic protrusion predicts clinical progression of benign prostatic enlargement in patients receiving medical treatment. International journal of urology 17, 69-74.

Lokeshwar, S. D., Harper, B. T., Webb, E., Jordan, A., Dykes, T. A., Neal Jr, D. E., Terris, M. K., and Klaassen, Z. (2019). Epidemiology and treatment modalities for the management of benign prostatic hyperplasia. Translational andrology and urology 8, 529.

Miklos, I., Mureşanu, H., Greluş, A., and Ioiart, I. (2018). IPSS Score Proves Its Clinical Relevance in Benign Prostate Hypertrophy Diagnosis and Follow-Up. Romanian Journal of Urology 17, 16-22.

Nunzio*, C. D., Tema, G., Lombardo, R., Cindolo, L., Bada, M., Cancrini, F., Nacchia, A., Ships, L., Gacci, M., and Milanesi, M. (2019). PD19-01 DETRUSOR WALL THICKNESS DOES NOT PREDICT A SUCCESSFUL TRIAL WITHOUT CATHETER AFTER ACUTE URINARY RETENTION IN PATIENTS ON MEDICAL TREATMENT FOR BENIGN PROSTATIC HYPERPLASIA. The Journal of Urology 201, e371-e372.

Park, H. K., Choo, G. Y., Chung, H., Paick, S. H., Kim, H. G., Kim, H. S., Lho, Y. S., Hong, W. S., and YANG, S. K. (2013). Effect of intravesical prostatic protrusion on the characteristics of lower urinary tract symptom change after 12‐week drug medication: a prospective analysis. LUTS: Lower Urinary Tract Symptoms 5, 1-4.

Park, H. Y., Lee, J. Y., Park, S. Y., Lee, S. W., Kim, Y. T., Choi, H. Y., and Moon, H. S. (2012). Efficacy of alpha blocker treatment according to the degree of intravesical prostatic protrusion detected by transrectal ultrasonography in patients with benign prostatic hyperplasia. Korean Journal of Urology 53, 92-97.

Patel, P. M., Sweigert, S. E., Nelson, M., Gupta, G., Baker, M., Weaver, F. M., and McVary, K. T. (2020). Disparities in benign prostatic hyperplasia progression: predictors of presentation to the emergency department in urinary retention. The Journal of Urology 204, 332-336.

Roehrborn, C. G. (2011). Male lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). Medical Clinics 95, 87-100.